Phase III trial success for M 923 (adalimumab biosimilar)-Baxalta + Momenta Pharma
Baxalta Incorporated and Momenta Pharmaceuticals, Inc. announced that M 923 met the primary endpoint in a randomized, double-blind, three-arm, parallel group, single-dose study. The primary objective of the study was to evaluate the pharmacokinetics of M923 compared to both U.S. and EU sourced Humira (adalimumab) reference products. In addition to showing bioequivalence in pharmacokinetics, this study also evaluated safety, tolerability and immunogenicity following single doses of M 923 given by injection. The safety profile and immunogenicity were also found to be comparable. A total of 324 healthy volunteers were enrolled in the study.
Comment: Baxalta and Momenta announced the initiation of a separate pivotal clinical trial of M 923 in chronic plaque psoriasis in October 2015. The companies are targeting a first regulatory submission in 2017 and a first commercial launch as early as 2018.
Comment: The patents protecting Humira from biosimilar competition are set to expire at the end of 2016,( though AbbVie claims patents extend to 2022 and beyond) and a growing number of competitors are advancing to the market. Amgen has submitted its biosimilar candidate for FDA approval, and following is a group that includes Novartis/Sandoz and Merck which is working with Samsung Bioepis.
When it comes to psoriasis, a knowledgeable healthcare professional is highly valued by patients (Pariser et al., 2016). With this in mind, we created The Psoriasis Academy, an online hub featuring succinct and easily accessible information for all healthcare professionals who want to know more about psoriasis and keep up to date with the latest developments.
Related news and insights
Genentech/Roche announced that the FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with wet, or neovascular, age-related macular degeneration (AMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections.
Oncopeptides announced that the company has decided to withdraw Pepaxto (INN melphalan flufenamide) from the market in the US, following the phase III OCEAN study, which showed an overall survival in the ITT population with a HR of 1.104. The decision has been made after interactions and dialogue with the FDA. Pepaxto was granted accelerated approval on February 26th 2021.
Johnson & Johnson announced the FDA has issued Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson & Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine.